Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era
- 19 April 2020
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 34 (12), 3338-3347
- https://doi.org/10.1038/s41375-020-0830-0
Abstract
The outcomes of patients with primary plasma cell leukemia (pPCL) after undergoing hematopoietic cell transplantation (HCT) in the novel agent era are unknown. We report outcomes of 348 patients with pPCL receiving autologous (auto-) HCT (n = 277) and allogeneic (allo-) HCT (n = 71) between 2008 and 2015. Median age was 60 years and 56 years for auto- and allo-HCT respectively. For auto-HCT, the 4-year outcomes were: non-relapse mortality (NRM) 7% (4–11%), relapse (REL) 76% (69–82%), progression-free survival (PFS) 17% (13–23%), and overall survival (OS) 28% (22–35%). Karnofsky performance status (KPS) > 90 and ≥very good partial response (VGPR) predicted superior OS in multi-variate analysis for auto-HCT. For allo-HCT, the 4-year outcomes were: NRM 12% (5–21%), REL 69% (56–81%), PFS 19% (10–31%), and OS 31% (19–44%). Compared with prior CIBMTR pPCL patients (1995–2006), inferior survival was noted in the current cohort (3-year OS, 39% vs. 38% in allo-HCT, and 62% vs. 35% in auto-HCT) respectively. However, we noted an increased HCT utilization, from 12% (7–21%) in 1995 to 46% (34–64%) in 2009 using SEER data (available till 2009). Despite modern induction translating to higher proportion receiving HCT, the outcomes remain poor in pPCL patients, mainly derived by high relapse rates post-HCT.Keywords
This publication has 34 references indexed in Scilit:
- Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocolsLeukemia, 2012
- Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant ResearchLeukemia, 2011
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab EraJournal of Clinical Oncology, 2010
- Primary plasma cell leukemia and autologous stem cell transplantationHaematologica, 2010
- Lenalidomide, Melphalan, and Prednisone Association Is an Effective Salvage Therapy in Relapsed Plasma Cell LeukaemiaJournal of Oncology, 2009
- Primary plasma cell leukemiaCancer, 2009
- Frequent upregulation of MYC in plasma cell leukemiaGenes, Chromosomes and Cancer, 2009
- Managing plasma cell leukemiaLeukemia & Lymphoma, 2007
- Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia.Leukemia & Lymphoma, 2007
- Bortezomib is an efficient agent in plasma cell leukemiasInternational Journal of Cancer, 2004